Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
22.08. | H.C. Wainwright senkt Kursziel für Bicara Therapeutics wegen höherer Ausgaben auf 40 US-Dollar | 1 | Investing.com Deutsch | ||
19.08. | Piper Sandler initiates Bicara Therapeutics stock with Overweight rating | 2 | Investing.com | ||
12.08. | Bicara Therapeutics reports Q2 results | 3 | Seeking Alpha | ||
12.08. | Bicara Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
12.08. | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | 1.187 | GlobeNewswire (Europe) | Updated data from Phase 1/1b trial presented at 2025 ASCO Annual Meeting demonstrated deep and durable responses in 1L HPV-negative R/M HNSCC Data from additional Phase 1/1b expansion cohorts evaluating... ► Artikel lesen | |
BICARA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
11.06. | Relay Therapeutics beruft Bicara-CEO in den Vorstand vor Brustkrebsstudie | 17 | Investing.com Deutsch | ||
09.06. | Stifel behält Kaufempfehlung und Kursziel von 48 US-Dollar für Bicara Therapeutics bei | 7 | Investing.com Deutsch | ||
09.06. | Stifel maintains Buy rating, $48 target on Bicara Therapeutics stock | 1 | Investing.com | ||
06.06. | Bicara Therapeutics Inc. - 8-K, Current Report | 3 | SEC Filings | ||
03.06. | Cantor Fitzgerald maintains overweight rating on Bicara stock | 2 | Investing.com | ||
02.06. | 'Our data is resonating far more with the people that matter,' Bicara CEO says amid Merus race | 1 | FierceBiotech | ||
02.06. | Stifel bekräftigt Kaufempfehlung für Bicara Therapeutics-Aktie | 1 | Investing.com Deutsch | ||
02.06. | Stifel reiterates Buy rating on Bicara Therapeutics stock | 1 | Investing.com | ||
02.06. | Cantor Fitzgerald reiterates overweight rating on Bicara Therapeutics stock | - | Investing.com | ||
01.06. | ASCO: Bicara ties antibody to 46% 2-year survival rate for head and neck cancer subset | 1 | FierceBiotech | ||
01.06. | Bicara Therapeutics Inc.: Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 | 199 | GlobeNewswire (Europe) | Median DOR of 21.7 months with 80% of responders achieving a deep response (=80% tumor shrinkage) Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46%... ► Artikel lesen | |
24.05. | Stifel maintains Bicara stock Buy rating, $48 target post-ASCO | 1 | Investing.com | ||
23.05. | Bicara Therapeutics Shares Sink Over 43% On Mixed Phase 1/1b Trial Results: What's Going On? | 2 | Benzinga.com | ||
23.05. | Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics | 2 | Investor's Business Daily | ||
23.05. | Bicara falls after early-stage trial data for head and neck cancer therapy | 1 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 40,190 | -0,99 % | Qiagen: Neue Wandelschuldverschreibungen über 750 Mio. USD | Qiagen hat die Ausgabe von Wandelschuldverschreibungen mit Netto-Aktienausgleich beschlossen. Das Volumen beläuft sich auf 750 Millionen US-Dollar, die Stückelung beträgt jeweils 200.000 US-Dollar.... ► Artikel lesen | |
MINERALYS THERAPEUTICS | 28,860 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
EVOTEC | 5,790 | -4,64 % | Die Blaupause für KI-Medikamentenentwicklung: So nutzen Evotec, NetraMark Holdings und BioNTech die neuen Möglichkeiten | Die Pharmabranche befindet sich mitten in einer Revolution. Künstliche Intelligenz verkürzt die Wirkstoffentwicklung von Jahren auf Monate und steigert die Trefferquote dramatisch. Datengetriebene Prognosen... ► Artikel lesen | |
BIONTECH | 86,80 | -0,52 % | BRISANTE Meldung setzt BioNtech Aktionäre unter Zugzwang. Bitte reagieren Sie jetzt sofort! | ||
AVIDITY BIOSCIENCES | 47,230 | +1,48 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 4,660 | 0,00 % | If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today | ||
ARS PHARMACEUTICALS | 11,105 | -4,35 % | ARS Pharma drops 9% as Lupin files application for generic neffy | ||
ADMA BIOLOGICS | 17,200 | -0,32 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
TECTONIC THERAPEUTIC | 16,650 | 0,00 % | Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025 | Data confirmed TX45's tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 23,840 | 0,00 % | H.C. Wainwright hebt Kursziel für Summit Therapeutics auf 50 US-Dollar an | ||
HARMONY BIOSCIENCES | 37,090 | +0,49 % | Harmony Biosciences Holdings, Inc.: Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress | Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will present data from its rare epilepsy pipeline at the 36th International Epilepsy Congress (IEC) being held August 30... ► Artikel lesen | |
ARCELLX | 69,75 | 0,00 % | Arcellx, Inc. (ACLX) Reports 97% Response Rate in CAR-T Trial | ||
TARSUS PHARMACEUTICALS | 58,59 | +0,02 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
VERA THERAPEUTICS | 22,610 | +1,44 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
VALNEVA | 3,502 | -6,86 % | Das sind Bewegungen! Kaufrausch bei Novo Nordisk und PanGenomic Health, Valneva im Abseits | In den BioTech-Sektor ist wieder Bewegung gekommen! Während Novo Nordisk nach drei Gewinnwarnungen nun endlich einen Boden gefunden hat, geht es bei Pangenomic Health munter weiter mit dem Aufwärts-Rhythmus.... ► Artikel lesen |